Dedicated navigation support facilitates access to your prescribed cancer drug across Hong Kong and the Mainland GBA8
Answer simple health-related questions, with no medical examination required
- Overview
- Featured benefits
Featured benefits
Value-added service
Cross-boundary Cancer Drug Support6
Join
*Now and Instantly Get 10% Discount on the First Year Premium^ of your AIA Vitality Insurance Plan
*Now and Instantly Get 10% Discount on the First Year Premium^ of your AIA Vitality Insurance Plan
- Improve your health with various activities
- Earn AIA Vitality points to upgrade your member status for more rewards
The higher status you reach, the higher premium discount** you will get
^ Only applicable to newly applied AIA Vitality insurance and subject to T&Cs
The content of this website does not contain the full terms and conditions of the policy and the precise terms and conditions of this plan are specified in the policy contract. You have the right to request a sample of policy contract before committing to the purchase. Please note the relevant product risks. You have the right to purchase FutureShield Cancer Drug Plan as a standalone plan without purchasing other insurance products at the same time.
Notes:
- The above information is for Hong Kong and Macau.
- All information here is for reference only. The product information in this webpage does not contain the full terms of the policy. For the details of the product features, terms and conditions, exclusions and key product risks, you may refer to the product brochure and policy contract of the relevant products. In case you want to read policy contract sample before making an application, you can obtain a copy from AIA.
- The FutureShield Cancer Drug Plan can only be purchased as a basic plan. You have the right to purchase FutureShield Cancer Drug Plan as a standalone plan without purchasing other insurance products at the same time.
- FutureShield Cancer Drug Plan only covers Covered Cancer Drugs and Supportive Medications which have been approved for such use by a recognised drug regulatory authority of the place where the medications are prescribed to and received by the insured.
- The term "Covered Cancer Drug(s)" means any pharmaceutical or biological medicinal product that is labelled as anti-cancer drug, and which has been approved by a recognised drug regulatory authority of such place where the cancer drug is prescribed to and received by the insured that the cancer drug is for the purposes of active treatment or palliative treatment and for targeting a Covered Cancer and any related complications (if applicable). Covered Cancer Drug shall specifically exclude any pharmaceutical or biological product used in surgery, radiotherapy, proton therapy or cell therapy. For details of the definition of "Covered Cancer Drug(s)", please refer to the policy contract.
- The term "Supportive Medication" means any pharmaceutical or biological medicinal product, other than the Covered Cancer Drug, which (a) is prescribed to the insured due to the medically necessary active treatment or palliative treatment of the insured's Covered Cancer, and (b) has been approved for such use by a recognised drug regulatory authority of such place where the Supportive Medication is prescribed to and received by the insured. Supportive Medication includes anti-nausea drugs, anti-rejection drugs, anti-vertigo drugs, anti-anodyne, and long-term medications which are required by the insured following the active treatment or palliative treatment of the insured's Covered Cancer such as hormone replacement therapy. For details of the definition of "Supportive Medication", please refer to the policy contract.
- If the insured is diagnosed with Covered Cancer more than 1 year after the later of the issue date and the latest commencement date of the policy, the plan will reimburse the eligible expenses under:
Cancer Drug Reimbursement Benefit: Covered Cancer Drug prescribed to the insured for medically necessary active treatment or palliative treatment of the insured's Covered Cancer, provided that the Covered Cancer Drug is prescribed to and received by the insured in a public hospital in Hong Kong or Macau, or in a hospital in Chinese Mainland.
Supportive Medication Reimbursement Benefit: Supportive Medication prescribed to the insured due to medically necessary active treatment or palliative treatment of the insured's Covered Cancer, provided that the Supportive Medication is prescribed to and received by the insured in a public hospital in Hong Kong or Macau, or in a hospital in Chinese Mainland.
All eligible expenses incurred by the insured and reimbursed by us under the Cancer Drug Reimbursement Benefit and the Supportive Medication Reimbursement Benefit will be counted towards and are subject to the Covered Cancer Limit, Covered Cancer Sub-limits, Lifetime Cancer Limit, the Lifetime Cancer Sub-limits and the maximum limits shown in the Benefits Schedule of product brochure.
The term "Covered Cancer(s)" refers to "Cancer" (as stated below) which (a) have been occurring for more than 1 year after the issue date or the latest commencement date of the policy, whichever is later, and (b) have been investigated, diagnosed, or treated or when its signs or symptoms have manifested. For details of the definition of "Covered Cancer", please refer to the policy contract.
The term "Cancer" means all stages of malignant cancer and carcinoma-in-situ, but will specifically exclude the following: (a) any tumour which is histologically classified as pre-malignant; (b) abnormal lesions of cervix uteri classified as cervical intra-epithelial neoplasia grade I (CIN I) and grade II (CIN II); and (c) any cancer where HIV infection is also present. The cancer must be confirmed by the insured's attending registered medical practitioner in writing and supported by clinical, radiological, histological or laboratory evidence reasonably acceptable to us. Please refer to the policy contract for details and the claim conditions.
Please refer to the product brochure and policy contract of FutureShield Cancer Drug Plan for details.
- Covered Cancer Limit and Covered Cancer Sub-limits are applicable to all Covered Cancers suffered by the insured and such limits will be replenished every 3 consecutive years, commencing from the date of first diagnosis of the first Covered Cancer suffered by the insured. Covered Cancer Limit and Covered Cancer Sub-limits shall become zero and the policy will terminate when the total amounts paid under Cancer Drug Reimbursement Benefit and Supportive Medication Reimbursement Benefit during the lifetime of the insured reaches the Lifetime Cancer Limit.
- The Cross-boundary Cancer Drug Support (the "Service") is a value-added service and does not form part of the contractual terms and benefits of any insurance policy, and is non-guaranteed. The Service is provided by the designated third-party service provider (the "Service Provider"), subject to the terms and conditions applicable to the Service. The Service is provided in Hong Kong and the designated cities within the Mainland GBA and not applicable in Macau. AIA reserves the right to amend, suspend or terminate the Service, any part thereof, service provider(s), or to change any terms and conditions relating thereto at any time without prior notice at its absolute discretion. For details of the Service and applicable limitations, please refer to the service leaflet or contact AIA for enquiry.
- The designated medical providers referred to above are designated medical providers and registered medical practitioners within the Service Provider's medical network in Hong Kong and the Mainland GBA that are available under the Cross-boundary Cancer Drug Support. For details, please refer to the service leaflet or contact the Service Provider's customer service hotline at (852) 2607 9655.
- "Greater Bay Area (GBA)" refers to the Guangdong-Hong Kong-Macau Greater Bay Area. "Mainland GBA" refers to the Guangdong-Hong Kong-Macau Greater Bay Area, excluding Hong Kong and Macau.
"Chinese Mainland" herein refers to the People's Republic of China excluding Hong Kong and Macau. "Hong Kong" and "Macau" herein refer to "Hong Kong Special Administrative Region" and "Macau Special Administrative Region" respectively.
* An annual membership fee will be charged for AIA Vitality and a member has to renew the AIA Vitality membership annually on time in order to maintain the membership and enjoy premium discount (if any) in the subsequent policy years. The membership fee of AIA Vitality may vary at any time without prior notice. Likewise, programme benefits may be added or removed without prior notice.
** Premium discount is only applicable to the standard premiums of selected AIA Vitality insurance products (including basic and add-on plans) and shall not apply to any extra premiums due to loading. In all circumstances, the premium discount will be calculated in accordance with the insured's AIA Vitality Status achieved on each policy anniversary. The policy anniversary of AIA Vitality selected insurance products and AIA Vitality membership anniversary may not be the same. For details and offers of AIA Vitality selected insurance products, please visit aia.com.hk/aiavitality.
Other related products
